{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:25:30Z","timestamp":1740461130222,"version":"3.37.3"},"reference-count":45,"publisher":"Informa UK Limited","issue":"33","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2024,10,20]]},"DOI":"10.1080\/14796694.2024.2391270","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T13:50:24Z","timestamp":1725371424000},"page":"2503-2508","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-3106","authenticated-orcid":false,"given":"Suresh S","family":"Ramalingam","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology","place":["Atlanta, USA"]},{"name":"Winship Cancer Institute of Emory University School of Medicine","place":["Atlanta, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7085-4640","authenticated-orcid":false,"given":"Jennifer W","family":"Carlisle","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology","place":["Atlanta, USA"]},{"name":"Winship Cancer Institute of Emory University School of Medicine","place":["Atlanta, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073474"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1321"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/1535370220959657"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00004-0"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes11111342"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0657"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0458"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.9638"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29042"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143472"},{"key":"e_1_3_6_13_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer v7.2024. \u00a9 National Comprehenseive Cancer Network Inc. 2023. All rights reserved. Accessed [July 2 2024]. To view the most recent complete version of the guideline go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way."},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02218-4"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.05.009"},{"key":"e_1_3_6_16_1","unstructured":"US Food and Drug Administration. FDA approves encorafenib with binimetinib for metastatic non-small cell lung cancer with a BRAF V600E mutation. News release. Accessed December 14 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-encorafenib-binimetinib-metastatic-non-small-cell-lung-cancer-braf-v600e-mutation"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11111102"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002891"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.009"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.05.006"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.7039"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502309"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00077-2"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30146-2"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30679-4"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00774"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.011"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408868"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02659"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08902"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.3116"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST20200485"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-023-04544-5"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1250"},{"key":"e_1_3_6_35_1","unstructured":"Braftovi (encorafenib). Prescribing information. Boulder CO: Array BioPharma Inc.; 2023."},{"key":"e_1_3_6_36_1","unstructured":"Mektovi (binimetinib). Prescribing information. Boulder CO: Array BioPharma Inc.; 2023."},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000891"},{"key":"e_1_3_6_38_1","unstructured":"Tafinlar (dabrafenib). Prescribing information. East Hanover NJ: Novartis Pharmaceuticals Corporation; 2024."},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.04.024"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.129"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2062"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_321483"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100324"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100460"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-613"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05510-4"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2024.2391270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T10:03:54Z","timestamp":1740391434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2024.2391270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":45,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2024,10,20]]}},"alternative-id":["10.1080\/14796694.2024.2391270"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2024.2391270","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}